This year’s Single Day Event in Basel Switzerland attracted a record 149 attendees, from 10 countries representing 30 companies. A diverse mix of professions from within the Pharmaceutical Industry contributed to the lively discussions, the broad networking opportunities and a better understanding and appreciation of their fellow attendees. The range of presentations from throughout the drug development cycle both inspired and engaged the audience, with the artistically creative keynote speaker setting the scene.
The pre-clinical stream was very well received with multiple attendees independently stating that they would highly appreciate similar programs in upcoming PhUSE events. While attendees of the SAS GD workshop stated that it was a valuable addition to their skill-sets.
The poster sessions and the networking was particularly appreciated, and we often had to physically herd people back to the auditorium. All-in-all, the attendees really immersed themselves into the day providing an unforgettable experience.
On behalf of PhUSE we would like to thank you for making the event.
Joseph & Karma
Introduction - Joseph Rowley and Karma Tarap, Novartis
Finding Truth and Beauty in Data - Moritz Stefaner MA, Independent
End Point Determination using Visual Analytics - Mark Lambrecht PhD, SAS Institute
The Simpler, the Better a Clinician's View on Data Visualisation - Lixin Zhang-Auberson M.D., PhD, Novartis
The Role of Information Visualisation in Health Technology Assessment
- Professor Martin Pitt, Exeter University Medical School
Spotfire: The Power of Interactive Visualisations for Safety Data Assessment
- Joel Allen, Roche and Michael Mertz, Novartis
Visualising Benefit-Risk for Drug Regulation
- Professor Ashby OBE, FMedDci, Co-Director, Imperial Clinical Trials Unit, Deputy Head, School of Public Health, Imperial College, London
Graphics of Clinical Data: The Good, the Bad and the Ugly
- Andreas Krause PhD, Actelion
Making the Complicated Obvious
- Dieter A. Haering, PhD, Novartis
Graphics of Clinical Data: The Good, the Bad and the Ugly - Andreas Krause PhD, Actelion
Making the Complicated Obvious - Dieter A. Haering PhD, Novartis
Visualising Benefit-Risk for Drug Regulation - Professor Ashby OBE, FMedDci, Co-Director, Imperial Clinical Trials Unit, Deputy Head, School of Public Health, Imperial College, London
The Role of Information Visualisation in Health Technology Assessment - Professor Martin Pitt, Exeter University Medical School
Spotfire: The power of Onteractive Visualisations for Safety Data Assessment - Joel Allen, Roche
Safety Data Assessment in Clinical Studies - Michael Merz, Novartis
PhUSE October 2014
- Chris Price, PhUSE
Preclinical Discussion Stream - Christina Wurelin and Frederic Mura
Visual Analytics in Risk-Based Monitoring (RBM) of Clinical Trials - Mark Demesmaeker, Integrated Clinical System Inc.
Visualising Data available in CDISC Dataset-XML Format - Monika Kawohl, Accovion GmbH
Memories of the Day:
Photos from the day
CDISC Therapeutic Area Standard User Guide Highlights
- Angelo Tinazzi, Cytel Inc
SEND Architecture Facilitates Harmonization and Aggregation of Data from Different Organisations/LIMS - Frederic Mura, Rich Buchanan, Laura Kaufman, Reto Aerni, Christina Wuermlin, Amelia Bedeoan, Michael Wasko, PDS Preclinical Data Systems Inc., Basel Switzerland and Mt. Arlington, NJ USA
Comparison of FDA and OpenCDISC SEND Validator v1.4.1 Rules - Laura Kaufman, Angela Popescu, Frederic Mura, Michael Wasko, Maro Schuster, Rich Buchanan, Amelia Bedeoan,PDS Preclinical Data Systems Inc.; Basel Switzerland and Mt Arlington, New Jersey USA
How to Design a Custom SDTM Domain for NonClinical Data Standards and Roadmap Team - Frederic Mura, PDS
2014 Computational Science Symposium (CSS) Working Groups Intro & Update - Dirk Spruck, Accovion
Industry Standard Good Programming Practices Guidance V1.0 now available
he PhUSE GPP Steering Board
Interactive Data Visualisation of Adverse Events Clinical Trial Data with the D3.js Script
Johann-Dan Laurent and Hugh McDevitt,
Advanced Quantitative Sciences, Programming Team – Novartis Pharma Development
Visualisation of Programming Metrics with Processing®
- Steve Densham, Georges Ette,
Novartis Pharma Development
Efficient Review of Source Data using Interactive Visualisation in R
Claire Petry,Advanced Quantitative Sciences Novartis Pharma Development
Visual Analytics for Risk-Based Monitoring (RBM) of Clinical Trials
Dr. Mark Demesmaeker, Integrated Clinical Systems
- Theorem Clinical Research
Exploiting Parameter - Based Programming
- David Garbutt, NNIT
How do I join the PhUSE Society?
There are two easy ways to join PhUSE:
1. Click through to the on-line registration website by clicking here.
2. Contact email@example.com for multiple membership applications or for invoicing arrangements.